FEDERAL POLICY MONITOR
Schedule III Cannabis Tracker
Track the federal cannabis rescheduling process, DEA milestones, policy catalysts, and market implications for MSOS and U.S. cannabis equities.
Research and monitoring only. No brokerage, trade execution, cannabis sales, or personalized financial advice.
Tracker Status
Status labels are derived from the federal-rescheduling event snapshot — monitoring context, not predictions.
- Current process
- Post-hearing briefing
- Hearing
- Concluded
- Post-hearing briefing
- Deadline passed August 17, 2026 — awaiting confirmation
- Medical classification
- Schedule III
- Broader cannabis classification
- Schedule I / unchanged
- Adult-use classification
- Schedule I / unchanged
- Current unresolved event
- August 17, 2026 — Post-hearing briefs / transcript corrections due August 17
- Next material event
- ALJ recommended decision (date not yet confirmed)
- Last updated
- Aug 31, 2026, 1:00 PM UTC
Latest Update
From the shared federal-rescheduling event feed. A hearing date does not guarantee Schedule III adoption.
DEA ALJ administrative hearing concluded
The DEA Administrative Law Judge hearing on federal cannabis rescheduling appears to have concluded. A hearing conclusion does not determine the final scheduling outcome.
Last updated: Aug 31, 2026, 1:00 PM UTC
DEA Hearing Calendar
Shares the same next material event as this tracker.
Why investors monitor this
- 280E tax treatment
- Institutional participation
- MSOS sentiment
- Sector liquidity
Current Status
Cannabis rescheduling remains one of the most important federal policy catalysts for the U.S. cannabis sector. Process status below is generated from normalized federal-rescheduling events.
Federal rescheduling overview
Deterministic process summary from the shared snapshot. Outcomes and timing are not certain and may change as the administrative process advances.
The administrative hearing has concluded and the post-hearing briefing deadline has passed. Filing or closure confirmation is still pending.
- Medical classification
- Schedule III
- Broader / adult-use classification
- Schedule I / unchanged · adult-use Schedule I / unchanged
- Hearing / briefing status
- Concluded · Deadline passed August 17, 2026 — awaiting confirmation
- Market relevance
- 280E tax treatment, institutional access, sector liquidity, and MSOS-linked sentiment
FDA-approved and/or state-licensed medical marijuana categories moved to Schedule III; adult-use/broader cannabis remains Schedule I pending broader rulemaking.
Source: AG Order No. 6754-2026
Source: AG Order No. 6754-2026
Next major step: ALJ recommended decision
Key Milestones
A procedural map of the federal rescheduling path. Status labels are derived from normalized events — monitoring context, not predictions.
HHS rescheduling recommendation
CompletedThe Department of Health and Human Services scientific review and recommendation transmitted to the Drug Enforcement Administration.
Market relevance: Established the policy direction investors monitor, though the DEA retains independent rulemaking authority and timing is not fixed.
Source: DEA Judge Issues Order On Marijuana Rescheduling Hearing Transcript Corrections
DEA proposed rule / NPRM
CompletedDate: August 25, 2026
Formal federal rulemaking to evaluate cannabis scheduling under the Controlled Substances Act.
Market relevance: Rulemaking headlines often move cannabis equity sentiment before operational or tax effects are realized.
Public comment period
CompletedA formal comment window allowing stakeholders to submit written input on the proposed rule. Distinct from later post-hearing briefs.
Market relevance: Comment volume and themes can signal industry positioning and potential procedural delays without predicting outcomes.
Administrative hearing
CompletedContested rescheduling proceedings before a DEA Administrative Law Judge.
Market relevance: Hearing activity and procedural rulings are frequent sector-sentiment catalysts.
Post-hearing briefs / transcript corrections
ActivePost-hearing briefing and transcript-correction deadlines after the administrative hearing record closes.
Market relevance: Briefing deadlines mark the bridge between hearing conclusion and the ALJ recommended decision.
ALJ recommended decision
UpcomingThe Administrative Law Judge issues a recommended decision for the DEA Administrator. Recommendations are not final agency action.
Market relevance: Markets may reprice timing expectations, but a recommendation is not a final scheduling change.
DEA Administrator action
UpcomingFinal agency decision/action by the DEA Administrator following the ALJ recommendation.
Market relevance: Administrator action is the primary agency decision investors monitor for broader scheduling outcomes.
Final rule / order
UpcomingPublished final rule or order defining any federal scheduling change and its scope.
Market relevance: Scope and effective-date details matter more than headline labels for tax and institutional narratives.
Effective date
UpcomingThe date any final scheduling change takes effect for covered categories.
Market relevance: Implementation timing can diverge from headline policy moves; breadth and liquidity often reveal how markets process the change.
Judicial review / stay
UpcomingCourt challenges or stays that may affect implementation timing without guaranteeing any outcome.
Market relevance: Litigation headlines can move sentiment independently of the administrative calendar.
Why Schedule III Matters
Policy and market structure themes investors commonly monitor during rescheduling — without implying investment outcomes.
280E tax exposure
Schedule III reclassification is widely discussed in connection with Section 280E limitations on cannabis operators. Any change would need clear regulatory interpretation before cash-flow effects are understood.
Institutional participation
Federal scheduling influences how institutions frame cannabis exposure, custody, and compliance. Policy progress does not automatically translate into capital flows.
U.S. operator cash flow
Multi-state operators may be sensitive to tax and regulatory narratives tied to rescheduling, even when state-level operations remain the primary business driver.
MSOS and cannabis ETF sentiment
MSOS and related ETFs are often used as liquid proxies for U.S. cannabis equity sentiment, making them common focal points during federal policy developments.
Liquidity and breadth
Rescheduling headlines can coincide with shifts in sector participation, volume, and which names lead or lag — useful context beyond a single headline.
Policy credibility
The perceived durability of federal cannabis policy affects how investors weigh headline risk versus structural sector trends over time.
What We’re Watching
Signals and developments that help separate procedural updates from market participation.
Policy process
DEA procedural calendar
Federal Register filings, hearing notices, and agency docket updates that advance or pause rulemaking.
Administrative hearing developments
Scheduling, testimony, and procedural rulings that may extend or compress the rescheduling timeline.
Federal Register updates
Published proposed and final rules, comment deadlines, and official agency statements.
Litigation or delay risk
Court challenges or procedural disputes that could affect implementation timing without guaranteeing any outcome.
Congressional reactions
Legislative proposals, oversight hearings, and committee commentary that may run parallel to DEA rulemaking.
Market response
Cannabis equity breadth and volume response
Whether policy headlines coincide with broader sector participation or remain isolated to a narrow set of names.
MSOS relative strength versus operators
ETF versus single-name performance can reveal how markets are distributing rescheduling-related sentiment.
Market Lens
CannaSetups helps distinguish policy headlines from actual market participation by combining rescheduling context with MSOS price action, breadth, liquidity, relative strength, positioning, sentiment, and sector rotation.
- MSOS price action
- Breadth
- Liquidity
- Relative strength
- Positioning and sentiment
- Sector rotation
Latest Weekly Review
Use the latest public issue to see how policy catalysts are showing up in MSOS, breadth, liquidity, and cannabis sector rotation.
CannaSetups provides market research and monitoring tools only. It does not provide brokerage services, trade execution, cannabis sales, or personalized financial advice.